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Abstract
Polymorphous adenocarcinoma (PAC) is the second most common malignant salivary gland tumour of minor salivary glands.
Human tissue kallikreins (KLKs) are a family of highly conserved serine proteases expressed by various tissues and organs.
The literature demonstrates a link between KLKs and salivary gland neoplasms. The purpose of this study was to determine
levels of KLK mRNA in tissue samples of PAC and to determine if KLK expression is limited to tumour cells. Nineteen
cases of PAC were reviewed (1987–2013). The diagnosis was confirmed, demographic data was collected, and formalin fixed
paraffin-embedded PAC and normal salivary gland tissue samples were obtained. RNA isolation was achieved, followed by
conversion to complementary DNA via reverse transcription. Using PCR, the quantitative level of expression of KLKs1–15
was recorded. Samples exhibiting high and low KLK expression were selected for immunohistochemistry staining. Results
revealed a statistically significant increase in mean KLK mRNA expression for KLK1, KLK4, KLK10, KLK12 and KLK15
in PAC tissue samples, compared with normal salivary gland tissue (Mann–Whitney U test, p < 0.05). Immunohistochemistry results demonstrated that KLKs were present in tumor cells. Notably, all samples demonstrating relatively higher KLK
mRNA expression showed equivalent or increased staining scores relative to the low KLK mRNA expression samples. In
conclusion, there appears to be aberrant kallikrein expression in polymorphous adenocarcinoma, suggesting the possibility
of a kallikrein cascade influence on tumor development and progression.
Keywords Tissue kallikreins · Immunohistochemistry · Salivary gland neoplasms · Adenocarcinoma · Reverse transcriptase
polymerase chain reaction

Introduction
Salivary gland tumours comprise 2–6.5% of all head and
neck neoplasms and have a global incidence of approximately 1–6.5 cases per 100,000 persons annually [1].
Polymorphous adenocarcinoma (PAC) is a malignant epithelial tumour characterized by cellular uniformity, morphologic diversity, an infiltrative growth pattern, and low
metastatic potential [2]. It is noteworthy that in the latest
World Health Organization (WHO) classification, the term
“low-grade” was dropped from its previous designation of
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“polymorphous low-grade adenocarcinoma”, to allow for
flexibility in grading [2]. Most commonly, it presents as a
firm, non-tender swelling of the palate, buccal or lip mucosa
[3].
The diagnostic challenge PAC poses is its histomorphologic resemblance and growth pattern overlap with
pleomorphic adenoma (PA) and adenoid cystic carcinoma
(ACC) [4–6]. In an attempt to improve diagnostic accuracy
in salivary gland pathology, many groups have examined
the immunohistochemical profile of PAC and its associated
biomarkers; however, none of these biomarkers have been
used independently in the diagnosis and prognosis of PAC
[7]. PRKD1 is a gene that encodes a kinase protein, which
has been implicated in conferring a neoplastic advantage to
PAC tumour cells [6].
Human kallikreins (KLKs) are secreted serine proteases,
with a range of physiologic and pathologic functions [8].
They are 15 of 178 human serine proteases belonging to the
S1A subfamily [9]. KLKs have emerged as powerful tumour
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markers, with the most well-known biomarker being KLK3
(prostate specific antigen or PSA), a valuable aid for prostate
cancer diagnosis and monitoring [8–11]. KLKs have been
studied as potential biomarkers for a variety of other malignancies, and specific KLKs have demonstrated association
with an unfavourable prognosis. KLKs4–7, KLK10, KLK11,
and KLK15 have been used as biomarkers for ovarian cancer; KLK5, KLK7, KLK10 and KLK14 for breast cancer;
and KLK7, KLK10, and KLK14 for colon cancer [9, 12–18].
To date, no KLK has been used as a biomarker in salivary
gland malignancies though most have been detected in salivary gland tissue. KLKs are potentially useful biomarkers
to aid in diagnosis, prognosis, and monitoring of salivary
gland neoplasms [19–22].
We hypothesize that specific KLKs are aberrantly regulated in PAC, as compared to normal salivary gland tissue
(NSGT). Furthermore, we postulate that KLK expression,
whether increased or decreased, may be demonstrated specifically in tumour cells.
This study aimed to determine levels of KLK
(KLKs1–15) mRNA in formalin fixed paraffin embedded
PAC tissue cases, using real time polymerase chain reaction.
A second aim was to determine if KLK expression is tumour
cell specific, by analyzing immunohistochemical expression
of specific KLKs in PAC tissue cases.
The study was approved by the Western University
Research and Ethics Board, Project ID 103783. The study
was performed in accordance with the ethical standards as
laid down in the 1964 Declaration of Helsinki.

Materials and Methods
Tumour Criteria
Cases of polymorphous adenocarcinoma (PAC) were
retrieved from the archives between 1987 and 2013 at University Hospital, London Health Sciences Centre and the
Division of Oral Pathology, Schulich School of Medicine
and Dentistry, Western University. Original hematoxylin and
eosin (H&E) stained slides were reviewed to confirm a diagnosis of PAC. Blocks of formalin fixed, paraffin embedded
(FFPE) PAC tissues were obtained for suitable cases. A total
of 19 PAC tumors were obtained.

Patient Data Collection from PAC Cases
Data gathered included patient age, gender, tumour clinical
features (site, recurrence) and microscopic findings (encapsulation, degree of infiltration, morphology, perineural invasion). Patient demographics are summarized in Table 1.
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Table 1  Patient demographics
All specimens
n
Age range
Gender
Tumour location

19
17–83
Female
13
Palate

Buccal mucosa

Male
6
Lip

11

5

2

Sublingual
gland
1

RNA Isolation from Formalin‑Fixed,
Paraffin‑Embedded Tissue
Regions representative of PAC tissue were circled and
matched to the same region on the FFPE tissue block. A
microtome (Microm HM 325, GMI, Inc., Ramsey, MN,
USA, SKU# 8243 30 1006) was used to prepare 3 × 10 μm
tissue curls from each of the PAC FFPE tissue blocks and
were then placed in 1.5 mL collection tubes. KLK mRNA
expression in normal salivary gland tissues was used as a
control. Tissues were deparaffinised and subsequent centrifugation was completed for 2 min at maximum speed
(12,000–14,000 × g). The supernatant was discarded and
centrifugation was repeated with subsequent removal of
residual fluid. Cases were then incubated with the collection tube open in a heating block for 5–15 min at 55 °C to
air dry the tissue pellet.
High pure FFPE RNA Micro Kit (Roche Applied Science, Mannheim, Germany, Catalogue Number 04 823 125
001) was used to isolate RNA from each of the cases, following manufacturer’s instructions. Pure total RNA was
obtained as a result and was stored at − 80 °C.
Isolated pure total RNA was centrifuged for 2 min at
maximum speed; the supernatant was transferred to a fresh
collection tube to be quantified. Qubit Fluorometer (Invitrogen, Carlsbad, CA, Catalogue No. Q32866) was used
to measure RNA. A minimum of 0.32 ng of RNA was
required for further experimentation.

cDNA Synthesis from Isolated RNA
The iScript cDNA synthesis kit [Bio-Rad Laboratories (Canada) Ltd., Mississauga, ON, Catalogue Number 1708890] was used to synthesize complementary
DNA (cDNA) from previously isolated RNA. A master
tube of iScript Reaction Mix and iScript Reverse Transcriptase was prepared. Reaction tubes were prepared,
each with a variable amount of tumour RNA and cDNA
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Table 2  cDNA synthesis
Case number

Enzyme/
buffer mix
(μL)

RNA (μL)

Nucleasefree H2O
(μL)

Total
volume
(μL)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

5
5
5
5
5
5
5
5
5
5
5
5
5
–
5
5
5
–
–

3.5
2.5
4.0
4.0
1.5
0.5
2.5
5.0
1.0
1.5
0.5
1.5
0.5
Too low
3.0
1.0
2.0
Too low
Too low

11.5
12.5
11.0
11.0
13.5
14.5
12.5
10.0
14.0
13.5
14.5
13.5
14.5
–
12.0
14.0
13.0
–
–

20
20
20
20
20
20
20
20
20
20
20
20
20
–
20
20
20
–
–

Table 3  Qiagen catalogue numbers for primer assays used in custom
PCR plate
Primer assay

Catalogue number

KLK1
KLK2
KLK3
KLK4
KLK5
KLK6
KLK7
KLK8
KLK9
KLK10
KLK11
KLK12
KLK13
KLK14
KLK15
β-Actin

QT00020664
QT00088466
QT00027713
QT00495159
QT00010437
QT00013972
QT00028343
QT00017689
QT00057190
QT00039816
QT00011011
QT00067977
QT00029876
QT00039928
QT00035735
QT01680476

Immunohistochemistry
Case Selection

was synthesized according to manufacturer’s instructions
(Table 2).

SYBR Green Real Time Polymerase Chain Reaction
(PCR)
The CFX Connect Real Time PCR Detection System [Bio-Rad
Laboratories (Canada) Ltd., Mississauga, ON] was used to
run the RT-qPCR reactions. Qiagen provided custom 96 well
PCR plates, each containing primer assays for KLK1–15 and
β-actin (reference gene) (Table 3). Six PAC cases were added
per plate. RT2 SYBR® Green qPCR Mastermix (Qiagen,
Toronto, ON, Catalogue No. 330500) was used to complete
the real-time PCR experiment and contained the following
reagents: RT-PCR buffer, hot start Taq DNA polymerase,
nucleotides, and SYBR green dye. Data generated was analyzed by ΔΔCT using CFX Manager. For each KLK, the mean
of mRNA expression in tumour cases was calculated, as was
the standard error of mean. Non-parametric statistical analysis,
specifically Mann–Whitney U Test, was completed. Statistical
significance was set at p < 0.05.

Cases were selected for immunohistochemistry after analyzing KLK mRNA levels from PCR data and tissues exhibiting
relatively lower or higher mRNA levels of specific KLKs
were included. KLK antibodies, including rabbit polyclonal
antibodies were obtained from the Diamandis Lab (University of Toronto, ON, Canada). Table 4 outlines the cases
used for immunohistochemistry experiments.
Paraffin Sections
Formalin fixed, paraffin embedded PAC tissue blocks from
cases of interest were obtained for immunohistochemistry. 5 μm Thick serial sections were cut using a microtome
(Microm HM 325, GMI, Inc., Ramsey, MN, USA, SKU#
8243 30 1006).

Table 4  Samples used for immunohistochemistry experiments
Specific KLK antibody

Case #
Low level

Case #
High level

KLK7
KLK8
KLK10
KLK11
KLK14

6
6, 16
11
6
6

16
11
6, 10
11
11

13
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Staining Procedure
A standard immunohistochemical staining method was
employed. An indirect technique was used to localize tissue
expression of cellular antigens, specifically expression of
KLK7, KLK8, KLK10, KLK11, and KLK14 in PAC tissue cases of interest. Positive controls were used for each
KLK antibody to ensure sensitivity, and included the following: ACC for KLK7, skin for KLK8 and KLK14, NSGT for
KLK10, and prostate for KLK11. Negative controls of the
PAC tissue were obtained by omitting the primary antibodies from the experiments. Optimal dilutions were as follows:
1:3200 for KLK7 and KLK14, 1:100 for KLK8, 1:1200 for
KLK10, and 1:2400 for KLK11.
Tissue sections were subjected to antigen retrieval, utilizing citrate buffer (pH 6.00), at 125 °C in a de-cloaking
chamber. The slides were rinsed in water, then PBS for 5 min
and subsequently blocked, using 10% horse serum at room
temperature. After 30 min, the appropriately diluted primary
antibodies, for the KLK of interest, were added to the slides
and incubated for the outlined optimal time. Excess antibody
was removed with a PBS rinse for 5 min. The ImmPRESS
kit (ImmPRESS ® Reagent Kit; Vector Laboratories, Burlingame, CA, Catalogue No. MP-7401) provided the antirabbit antibodies, conjugated with horseradish peroxidase
micropolymers; tissue sections were incubated with the
anti-rabbit antibodies for 30 min at room temperature. The
slides were then stained with 3, 3′-diaminobenzidine tetrahydrochloride (DAB Peroxidase Substrate Kit, Vector Laboratories, Burlingame, CA, Catalogue No. SK-4100) as the
chromogen, followed by a hematoxylin counterstain.
Data Collection and Statistical Analysis
for Immunohistochemistry
The KLK staining of each PAC case was viewed under light
microscopy and assessed semi-quantitatively, using a well
described method [21]. A proportion score (0–5), and an
intensity score (0–3) was used to evaluate each stained tissue case. These scores were then used to generate an overall
staining score (OSS).
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Table 5  RNA quantification
by Qubit Fluorometer for each
PLGA tissue sample

Case number

RNA (μg/mL)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

0.091
0.121
0.075
0.072
0.214
0.898
0.139
0.065
0.322
0.244
1.04
0.238
0.520
Too low
0.120
0.426
0.163
Too low
Too low

Table 6  Percentages of PLGA tissue samples expressing KLK1–15
and calculated p-values, as determined by Mann–Whitney U Test,
for the comparison of expression of KLK1–15 in PLGA tissues and
NSGT
KLK

PLGA (%)

p-value

KLK1
KLK2
KLK3
KLK4
KLK5
KLK6
KLK7
KLK8
KLK9
KLK10
KLK11
KLK12
KLK13
KLK14
KLK15

87.5
87.5
62.5
43.8
68.8
25
18.8
31.3
50
62.5
25
68.8
25
37.5
37.5

0.00672
0.82588
0.59612
0.03236
0.238
Sample number low
Sample number low
0.15854
0.71138
0.00804
Sample number low
0.0536
Sample number low
0.88076
0.00386

Results

Expression of KLKs in cDNA of PAC

RNA Isolation

The expression of KLK mRNA in cases of PAC was examined for KLK1–15. All cases of PAC tissue demonstrated
expression of at least 4 KLKs, with some showing as many
as 13 KLKs. The percentages of PAC tissues exhibiting each
KLK are listed in Table 6. KLK7 was the least likely to be
expressed in the cases, having just 18.8% expression. KLK6,

The RNA isolated from PAC cases is shown in Table 5. In
cases 14, 18, and 19, the RNA amount was not detectable.
The average amount of RNA obtained from the remaining
16 cases was 0.297 μg/mL.
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KLK11, and KLK13, having 25% expression in tissue cases,
were also expressed infrequently. KLK1 and KLK2 were
most commonly expressed.

Expression of KLKs in PAC Compared to Normal
Salivary Gland Tissue (NSGT)
The mean expression of each KLK was calculated for all
PAC cases. Figure 1a–e demonstrates statistically significant KLK mRNA expression in PAC tissues, as compared
to NSGT. Statistical significance was determined using
Mann–Whitney U Test, p < 0.05. For each KLK, the mean
mRNA expression was found to be greater in the PAC cases,
compared with the NSGT. This was statistically significant
for KLK1, KLK4, KLK10, KLK12, KLK15. The relative
fold change of mRNA expression for each KLK in PAC
versus NSGT is demonstrated in Fig. 1f. In each graph, the
bar-lines indicate the standard error of mean (SEM).

Immunohistochemical Staining Results
Representative immunohistochemical staining images
are shown in Fig. 2 of PAC tissue cases stained for particular KLKs. For each KLK antibody, at least one PAC
case demonstrating relatively high mRNA expression is

Fig. 1  a–e Mean value of KLKs1, 4, 10, 12, and 15 mRNA expression in PLGA vs NSGT and f relative fold increase of mRNA expression of KLK1-15 in PLGA tissue as compared with NSGT. Statistical
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presented. For each KLK antibody, at least one PAC case
demonstrating relatively low mRNA expression and one
PAC case demonstrating relatively high mRNA expression
are presented.
The IHC staining results are outlined in Table 7, with
total IHC scores for each case demonstrated in Fig. 3a.
Cases demonstrating relatively high KLK expression
exhibited staining of all tumour cells (grade 5) and the
intensity grade of the stains varied from 1 to 3. Cases
demonstrating relatively low KLK expression exhibited
staining of most tumour cells (grades 4–5) and the intensity grade of the stains varied from 1 to 3. With respect
to localization of a specific KLK, the cases with higher
mRNA expression demonstrated equivalent or increased
immunohistochemical staining, as compared with cases
with lower mRNA expression. Most of the IHC stains on
PAC cases showed primarily cytoplasmic staining, with
some exceptions. Nuclear cell staining was seen with
KLK7 (cases 6 and 16), KLK11 (cases 6 and 11), and
KLK14 (cases 6 and 11). KLK10 exhibited inflammatory
cell staining in case 10, and epithelial cell staining in case
11 (Fig. 3b). All cases demonstrated negative stromal
staining. Results from PCR KLK mRNA quantification
and IHC staining were compared and the findings are summarized in Table 8.

significance determined by Mann–Whitney U Test (p < 0.05), standard error of mean (SEM) is demarcated by the graph bars
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Fig. 2  (Left) comparative immunohistochemical localization of
KLK8 in PLGA, cases 6 and 11. a Case 6 demonstrated relatively low
KLK8 mRNA expression on PCR, b case 11 demonstrated relatively
high KLK8 mRNA expression on PCR. (Centre) comparative immunohistochemical localization of KLK10 in PLGA, cases 6 and 11: c
case 6 demonstrated relatively high KLK10 mRNA expression on
PCR, d case 11 demonstrated relatively low KLK10 mRNA expres-

sion on PCR. (Right) comparative immunohistochemical localization
of KLK14 in PLGA, cases 6 and 11: e case 6 demonstrated relatively
low KLK14 mRNA expression on PCR, f case 11 demonstrated relatively high KLK14 mRNA expression on PCR (images taken at × 200
original magnification, blue hematoxylin nuclear stain, brown diaminobenzidine/DAB chromogen)

Table 7  Immunohistochemistry (IHC) proportion score, intensity and overall score are recorded below, along with specific staining characteristics seen in each sample
Antibody Case # Level of mRNA Proportion
score

Intensity score IHC total score Stromal stain Other

KLK7
KLK7
KLK8
KLK8
KLK8
KLK10
KLK10
KLK10

6
16
6
16
11
11
6
10

Low
High
Low
Low
High
Low
High
High

5
5
4
4
5
5
5
5

2
2
1
1
1+
1/2
1
1

7
7
5
5
6+
5.5
6
6

–
–
–
–
–
–
–
–

KLK11

6

Low

5

2

7

–

KLK11

11

High

5

3

8

–

KLK14

6

Low

5

3

8

–

KLK14

11

High

5

3

8

–

13

Cytoplasmic and nuclear staining
Cytoplasmic and nuclear staining
Primarily cytoplasmic staining
Primarily cytoplasmic staining
All cytoplasmic staining
Epithelial positive cells
All cytoplasmic staining
All cytoplasmic staining; inflammatory cells
staining positively
Primary cytoplasmic staining; many nuclei
staining
Primary cytoplasmic staining; some positive
and negative nuclei
Primarily cytoplasmic staining; some nuclei
staining
Primarily cytoplasmic staining; much nuclear
staining

Immunohistochemistry experiments were used in the current study to determine if KLK upregulation in PAC was

High, 0.377251
Low, 0.1049704
7
6
8
8
High, 0.138793

6

High, 1.0
Low, 0.048942
High, 1.0
High, 1.0
7
5
6
7
8
Low, 0.0
Low, 0.0969368
High, 0.225234
Low, 0.0
Low, 0.02862
0.37725
0.09694
0.12312
0.44622
0.02862
0.45908
0.25982
0.27191
0.51035
0.18320

mRNA
Average level
of mRNA

Median value
of mRNA

Case 6
Total PLGA samples

IHC Demonstrates that KLK Upregulation is Specific
to PAC Tumour Cells

Table 8  Summary of PCR and IHC results for selected cases

PCR Data Suggests an Increase in all KLK Expression
in PAC

KLK7
KLK8
KLK10
KLK11
KLK14

mRNA
IHC score

Discussion

Through PCR we have demonstrated that KLK expression is
upregulated in PAC. The average levels of KLK1–15 mRNA
expressed in all PAC tissue cases were increased relative
to NSGT. This upregulation was statistically significant for
KLK1, KLK4, KLK10, KLK12, and KLK15 (p < 0.05).
KLK1 had the most statistically significant upregulation
in PAC as compared to NSGT with a p-value of 0.00672.
In particular, KLK6, KLK7, KLK11 and KLK13 exhibit
wide error bars; this is indicated by the lower percentages
of cases expressing these KLKs: 25%, 18.8%, 25% and 25%,
respectively.

mRNA

IHC score

mRNA

IHC score

Case 16
Case 11
Case 10

Fig. 3  a Immunohistochemistry stain results. IHC total score seen in
each case is shown. b Kallikrein 10 staining in salivary gland. Faint
staining is present in ducts and acinar cells (arrowheads), and some
staining is present in inflammatory cells (arrows) (× 200 original
magnification, blue hematoxylin nuclear stain, brown diaminobenzidine/DAB chromogen)

7
5

175
IHC score
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tumour cell-specific. Proportion scores for each PAC case
stained with KLK antibody revealed that most tumour cells
were staining positively with a proportion score 5, save for
two cases with KLK8 demonstrating scores of 4, indicating a slightly lower percentage of tumour cells taking up
stain. Intensity scores varied between cases. Ultimately, the
experiment was able to demonstrate that the upregulation of
KLKs in PAC was tumour-cell specific.

KLK mRNA Profile of PAC vs ACC, as Determined
by PCR
Recently, the expression of KLKs in ACC and PA has been
examined [23, 24]. Kerr et al. concluded that KLK1, KLK8,
KLK11 and KLK14 were significantly downregulated in
ACC, as compared to NSGT [23]. In the present study,
KLK1, KLK4, KLK10, KLK12, and KLK15 were found
to be significantly upregulated in PAC, when compared to
NSGT. These differences, specifically KLK1, which was
present in 73% of ACC cases studied by Kerr et al., and in
the present study, expressed in 87.5% of PAC cases, may
prove to be useful in distinguishing PAC from ACC [3–5,
23].
Morrison et al. recently investigated the KLK expression
profile in PA and found that mRNA expression of KLK1,
KLK12 and KLK13 was downregulated relative to NSGT
(p < 0.05) [24]. This finding was supported in immunostaining studies. Interestingly, a relative increased KLK1 protein
expression was noted in PA cases demonstrating capsular
perforation [24]. Taken together with the findings of the present study, which noted an upregulation in KLK1 in PAC,
KLK1 may infer more aggressive tumour behaviour. These
differences in IHC staining profiles may be useful in diagnostic distinction between PAC and PA.

Analysis of IHC Staining of KLKs in PAC
Overall, each case with a relatively higher expression of
KLK mRNA stained equivalently or with a higher IHC
score than the cases which had relatively lower KLK mRNA
expression. For KLK7, case 6 demonstrated no mRNA
expression, and case 16 showed relatively higher expression; however, both cases had equivalent IHC scores of 7.
Similarly, for KLK10, case 11 had relatively low mRNA
expression in comparison to cases 6 and 10, yet the IHC
score for all cases was 6. Furthermore, for KLK14, case 6
had relatively low mRNA expression in comparison to case
11; IHC scores for both cases were 8. A small increase was
seen between cases for KLK11, with case 6 demonstrating
zero mRNA and an IHC score of 7, while case 11 having
relatively higher mRNA expression and an IHC score of 8.
The most significant difference was seen with KLK8; cases 6
and 16 demonstrated relatively lower mRNA levels and had
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IHC scores of 5, while case 11 had relatively high mRNA
and an IHC score of 7. Additional IHC staining results note
that all cases demonstrated negative stromal staining.
The no to minimal differences in IHC scores between
cases with low and high mRNA expression may be explained
by a number of postulations. Reverse transcriptase PCR
determines the amount of mRNA, which is indicative of
transcription of KLK genes; however, IHC involves localizing the KLK protein in the tumour cells. It is possible that
while the tumour cells are increasing the rate of transcribing
the KLK genes, it can lead to prohibiting translation and as
a result, no protein is being made. Furthermore, we know
KLKs are secreted proteases, and the process of secretion
may be carried out at different rates, affecting the IHC staining characteristics.

IHC Staining of KLKs in Salivary Gland Neoplasia
KLK IHC staining profiles of salivary gland neoplasia,
as well as NSGT, have been well documented, including
KLK7, KLK8, KLK10 and KLK14. Hashem et al. noted that
KLK7 was significantly overexpressed in PA and ACC (OSS
7.0 and 7.5 respectively), when compared to NSGT (OSS
6.5) [25]. The PAC cases in this study, whether they had
relatively low or higher mRNA expression, both had OSS
of 7.0, which we can extrapolate as significantly increased
as compared to NSGT. In previous work by Darling et al.,
KLK8 was shown to be expressed in NSGT (OSS 7.0), and
to demonstrate equal or increased OSS in most malignancies: ACC (OSS 7.0 +/− 1.4), PAC (OSS 6.9 +/− 0.5), ACI
(OSS 7.0 +/− 0.8), ANOS (OSS 7.6 +/− 0.7) [20]. In the present study, OSS in relative low-expressing KLK8 mRNA
cases was 5, and in relatively higher expressing KLK8
mRNA cases was 7, which is reasonably consistent with
previous work. Darling et al. also described KLK10 as found
in NSGT (OSS 6.0), and no significant differences in KLK10
expression were seen in malignancy: ACC (OSS 5.8) [21].
PAC was not investigated in Darling et al.’s study; however,
in the present study, the OSS for KLK10 of our PAC cases
were consistent with the other salivary gland malignancies
(OSS 6 for all three cases). Hashem et al. noted KLK14 was
present in NSGT (OSS 6.5), and that, while KLK14 was
upregulated in PA (OSS 7.25), there were no significant differences seen in salivary gland malignancies: ACC (OSS
6.8) [22]. KLK14 stains in our PAC cases demonstrated OSS
of 8, despite differences in mRNA levels. Taken together,
KLK14 may be recognized as over-expressed in PAC. Darling et al. noted KLK7, KLK10 and KLK14 appeared to
be correlated in their expression in ACC, all demonstrating
no significant difference from NSGT. This same correlation
does not seem to be seen in our staining of PAC; KLK7 and
KLK14 show similar IHC profiles, but KLK10 shows lower
staining scores.

Head and Neck Pathology (2021) 15:169–178

In our experiments, we did not compare NSGT and PAC
staining, as we were interested in correlated data from PCR
(mRNA expression levels) with IHC, look to elucidate
tumour specific staining. However, by review previous works
that have used the same IHC protocol and staining scoring systems, this present study has added value to further
characterizing KLK IHC staining profiles in salivary gland
neoplasia.
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3.

4.

5.

Conclusion
Our study confirms the hypothesis that PAC demonstrate
aberrant expression of KLKs. We believe KLK upregulation
in PAC indicates the involvement of a complex proteolytic
cascade, and may more significantly involve KLK1, KLK4,
KLK10, KLK12, and KLK15. We suspect this upregulation
of KLK activity may be involved in regulating malignant
processes in PAC, and thus implicated in determining its
clinical characteristics, including indolent behaviour and
infrequent metastatic spread. Furthermore, the results of
this study significantly add to the KLK profile of salivary
gland neoplasia, at the mRNA and protein level. Importantly,
when combining the resultant KLK profile in PAC with the
recently elucidated KLK profile in ACC and PA, the resultant differences may render a diagnostic panel useful in differentiating between the malignancies.
Future studies should aim to identify an active proteolytic
cascade involving KLK1–15 in PAC tumours. Furthermore,
examining the PAC cases from our study for the PRDK1
hotspot mutation would be of value. To better elucidate the
function of KLKs in PAC, it would be beneficial to study the
effect of their activity or lack thereof on cancer cells.
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